AcelaBio is a state-of-the-art contract research organization delivering end-to-end histopathology and precision medicine laboratory services for pharmaceutical, biotech and academic institutions. AcelaBio provides high throughput digital pathology services to support multicenter global clinical trials and has the flexibility to develop and validate biomarker assays for novel or existing protein or molecular targets. AcelaBio’s laboratory capabilities are applicable across a wide range of therapeutic indications including gastroenterology, oncology, and dermatology. AcelaBio is highly specialized in testing gastrointestinal tissues from patients with inflammatory bowel diseases (e.g., Crohn’s disease and ulcerative colitis), eosinophilic gastrointestinal diseases (e.g., eosinophilic esophagitis), and liver diseases (non-alcoholic steatohepatitis). AcelaBio employs operational, scientific, and medical experts, including U.S. Board Certified pathologists, who are dedicated to delivering reliable, high-quality data and imagery.